<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00860730</url>
  </required_header>
  <id_info>
    <org_study_id>V10801</org_study_id>
    <nct_id>NCT00860730</nct_id>
  </id_info>
  <brief_title>PERCEVAL Pivotal Trial</brief_title>
  <official_title>PERCEVAL Pivotal Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LivaNova</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LivaNova</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The clinical investigation is designed as a prospective and non-randomised study on a maximum&#xD;
      of 150 patients. This study will be conducted at Investigational Centres in the European&#xD;
      Community. A minimum number of 8 European Centres will be involved in the clinical&#xD;
      investigation. A minimum of 15 patients will be enrolled at each Investigational Centre. The&#xD;
      clinical follow-up requires evaluations at discharge (or 30 days if the patient is still&#xD;
      hospitalized), 3-6 and 12 months following the procedure.The primary objective of this&#xD;
      clinical investigation is to assess the performance of the Perceval S valve at 3-6 months&#xD;
      after implantation in high surgical risk patients, who require a surgical intervention to&#xD;
      replace the aortic valve.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The design of the Perceval S prosthesis stems from the intention to offer an alternative to&#xD;
      traditional flexible prostheses (stented and stentless biological valves) using conventional&#xD;
      open-heart surgery. As a result of the sutureless implant procedure, in fact, patients could&#xD;
      benefit from:&#xD;
&#xD;
      Reducing aortic clamp times, with subsequent overall reduction of surgical timing and&#xD;
      therefore reduction in related risks; Avoiding to pass the stitches through the annulus and&#xD;
      sutures knotting, with consequent less risk of tearing aortic annulus and wall, damaging the&#xD;
      bundle of His, embolizing foreign material in the vascular system.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of the safety of the Perceval S prosthesis in terms of percentage incidence of mortality and morbidity at 3-6 months after implant</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of mortality and morbidity rates at discharge (or 30 days if the patient is still hospitalized) and 12 months after implant</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Aortic Valve Replacement</condition>
  <arm_group>
    <arm_group_label>Perceval S</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Aortic valve replacement with Perceval aortic heart valve</intervention_name>
    <description>Replacement of diseased or malfunctioning native aortic valve via traditional surgery (open chest) with the Perceval S prosthesis</description>
    <arm_group_label>Perceval S</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects of 75 years or older;&#xD;
&#xD;
          -  Subjects with aortic valve stenosis or steno-insufficiency;&#xD;
&#xD;
          -  Subjects at high surgical risk and candidates for aortic valve replacement with a&#xD;
             biological prosthesis;&#xD;
&#xD;
          -  Subjects in NYHA functional classes III and IV with the Logistic EuroSCORE greater&#xD;
             than 5%.&#xD;
&#xD;
          -  Subjects who have agreed to participation in the clinical evaluation and who have&#xD;
             signed the informed consent;&#xD;
&#xD;
          -  Subjects who are willing to undergo all the medical follow-ups and echocardiographic&#xD;
             examinations and laboratory tests that form part of this present protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects involved in any other clinical study for drugs or devices;&#xD;
&#xD;
          -  Subjects who have previously undergone implantation with the Perceval S prosthesis&#xD;
             being assessed;&#xD;
&#xD;
          -  Subjects with previous implantation of valve prostheses or annuloplasty ring in mitral&#xD;
             position;&#xD;
&#xD;
          -  Subjects requiring simultaneous procedures, apart from septal myectomy and/or coronary&#xD;
             by-pass;&#xD;
&#xD;
          -  Subjects with aneurysmal dilation or dissection of the ascending aortic wall needing&#xD;
             surgical correction;&#xD;
&#xD;
          -  Subjects needing non elective intervention;&#xD;
&#xD;
          -  Subjects with aortic annulus (after procedure for decalcification) of dimensions such&#xD;
             that the implantation of a valve of size 21 or 23 mm is not possible (direct&#xD;
             intra-operative measurement with sizer), in accordance with the indications reported&#xD;
             in the Investigator's Brochure;&#xD;
&#xD;
          -  Subjects with active endocarditis;&#xD;
&#xD;
          -  Subjects with active myocarditis;&#xD;
&#xD;
          -  Subjects with any anomaly of the coronary ostia determined through pre-operative&#xD;
             coronary angiogram or during intervention itself;&#xD;
&#xD;
          -  Subjects with congenital bicuspid aortic valve;&#xD;
&#xD;
          -  Subjects with aortic root enlargement, where the ratio between observed and expected&#xD;
             diameters (calculated as a function of age and patient body surface area) is &gt; 1.3;&#xD;
&#xD;
          -  Subjects with aortic root enlargement, where the ratio between the diameter of the&#xD;
             sino-tubular junction and the annulus diameter is &gt; 1.3;&#xD;
&#xD;
          -  Subjects with myocardial infarct &lt; =90 days;&#xD;
&#xD;
          -  Subjects with known hypersensitivity to nickel alloys.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>75 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Axel Haverich, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hannover Medizinische Hochschule</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Guillaume et René Laennec</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Mutualiste Montsouris</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Cardiologique du Haut-Lévêque</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ruhr Universität Bochum</name>
      <address>
        <city>Bochum</city>
        <zip>44789</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westdeutsches Herzzentrum</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inselspital Bern</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Switzerland</country>
  </location_countries>
  <link>
    <url>http://www.sorin.com</url>
    <description>Website</description>
  </link>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>March 11, 2009</study_first_submitted>
  <study_first_submitted_qc>March 11, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 12, 2009</study_first_posted>
  <last_update_submitted>January 17, 2019</last_update_submitted>
  <last_update_submitted_qc>January 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aortic valve replacement</keyword>
  <keyword>Aortic stenosis</keyword>
  <keyword>Biological valve</keyword>
  <keyword>Sutureless valve</keyword>
  <keyword>Stented valve</keyword>
  <keyword>Aortic Valve Disease</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

